18F-FDG PET/CT预测卵巢癌新辅助化疗联合尼达尼布后的肿瘤反应与二次探查手术结局:GINECO CHIVA II期试验的辅助分析
本研究为GINECO CHIVA II期试验的辅助分析,纳入24例FIGO IIIc-IV期卵巢癌患者,在接受新辅助化疗联合尼达尼布或安慰剂治疗一个周期后行18F-FDG PET/CT,采用EORTC和PERCIST标准评估代谢反应。结果显示两种标准对无进展生存期和总生存期的预测能力相似,且反应者接受完全细胞减灭术的比例更高;MATV和TLG变化未能预测生存。
要点
- PERCIST和EORTC标准对PFS和OS的预测能力相似。
- 代谢反应者接受完全细胞减灭术的比例显著高于非反应者。
- MATV和TLG变化未能预测PFS或OS,也未找到预测生存的最佳阈值。
核心结论
- 18F-FDG PET采用EORTC或PERCIST标准可用于卵巢癌试验中分析早期肿瘤反应,并预测二次探查手术结局和生存。
- PERCIST的优势在于ΔSULpeak与ΔCA-125相关,且PET反应比肿瘤标志物反应早1个月。
- MATV和TLG均不能用于预测生存。
研究设计与样本
- 本研究为GINECO CHIVA II期试验的辅助研究,纳入24例FIGO IIIc-IV期卵巢癌患者,其中10例接受化疗+安慰剂,14例接受化疗+尼达尼布。
- 由两名对治疗和结局盲法的读者进行中央 review,共识计算整个肿瘤负荷感兴趣区内PET参数的百分比变化。
- 采用EORTC和PERCIST标准将患者分类为反应者(部分代谢反应和完全代谢反应)或非反应者(稳定代谢疾病和进展代谢疾病)。
- 同时分析代谢活跃肿瘤体积(MATV)和总病灶糖酵解(TLG)的百分比变化。
主要发现
- PERCIST和EORTC标准在预测PFS和OS方面显示出相似的判别能力。
- MATV/TLG变化不能预测PFS或OS,且未找到MATV/TLG预测生存的最佳阈值。
- 完全细胞减灭术(无残留病变 vs 残留病变<0.25 cm/0.25-2.5 cm/>2.5 cm)在反应者中比非反应者更常见(PERCIST P=0.002,EORTC标准 P=0.02)。
- 基线至中期PET同期CA-125血水平变化与PET数据变化无相关性,但基线至第二周期后CA-125变化与ΔSULpeak有统计学显著相关。
关键数值与推荐
- PERCIST和EORTC标准用于分类代谢反应。
- 完全细胞减灭术在反应者中更常见:PERCIST P=0.002,EORTC标准 P=0.02。
- ΔSULpeak与ΔCA-125(基线至第二周期后)有统计学显著相关。
临床怎么用
- 在卵巢癌新辅助治疗试验中,可采用18F-FDG PET的EORTC或PERCIST标准早期评估肿瘤代谢反应。
- 代谢反应可预测二次探查手术完全细胞减灭术的成功率及生存结局。
- PERCIST标准下ΔSULpeak与CA-125变化相关,且PET反应早于肿瘤标志物反应1个月,可辅助临床决策。
- MATV和TLG不建议用于预测生存。
局限性
- 本研究为辅助研究,样本量较小(共24例)。
- 未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This ancillary study aimed to evaluate 18F-FDG PET parameter changes after one cycle of treatment compared to baseline in patients receiving first-line neoadjuvant anti-angiogenic nintedanib combined to paclitaxel-carboplatin chemotherapy or chemotherapy plus placebo and to evaluate the ability of 18F-FDG PET parameters to predict progression-free survival (PFS), overall survival (OS), and success of second-look surgery. MATERIALS AND METHODS: Central review was performed by two readers blinded to the received treatment and to the patients' outcome, in consensus, by computing percentage change in PET metrics within a volume of interest encompassing the entire tumor burden. EORTC and PERCIST criteria were applied to classify patients as responders (partial metabolic response and complete metabolic response) or non-responders (stable metabolic disease and progressive metabolic disease). Also analyzed was the percentage change in metabolic active tumor volume (MATV) and total lesion glycolysis (TLG). RESULTS: Twenty-four patients were included in this ancillary study: 10 received chemotherapy + placebo and 14 chemotherapy + nintedanib. PERCIST and EORTC criteria showed similar discriminative power in predicting PSF and OS. Variation in MATV/TLG did not predict PFS or OS, and no optimal threshold could be found for MATV/TLG for predicting survival. Complete cytoreductive surgery (no residual disease versus residual disease < 0.25 cm/0.25-2.5 cm/> 2.5 cm) was more frequent in responders versus non-responders (P = 0.002 for PERCIST and P = 0.02 for EORTC criteria). No correlation was observed between the variation of PET data and the variation of CA-125 blood level between baseline sample and that performed contemporary to the interim PET, but a statistically significant correlation was observed between ΔSULpeak and ΔCA-125 between baseline sample and that performed after the second cycle. CONCLUSION: 18F-FDG PET using EORTC or PERCIST criteria appeared to be a useful tool in ovarian cancer trials to analyze early tumor response, and predict second-look surgery outcome and survival. An advantage of PERCIST is the correlation of ΔSULpeak and ΔCA-125, PET response preceding tumor markers response by 1 month. Neither MATV nor TLG was useful in predicting survival. TRIAL REGISTRATION: NCT01583322 ARCAGY/ GINECO GROUP GINECO-OV119, 24 April 2012.
引用
- Aide N, Fauchille P, Coquan E, et al. Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 33221969. doi:10.1007/s00259-020-05092-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。